Premium
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors
Author(s) -
Tamiya H.,
Kamo R.,
Kumei A.,
Yanagihara S.,
Ishii M.,
Kobayashi H.
Publication year - 2012
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2011.04316.x
Subject(s) - angiosarcoma , sorafenib , scalp , immunohistochemistry , medicine , receptor , cancer research , vascular endothelial growth factor , vegf receptors , cell growth , pathology , biology , surgery , hepatocellular carcinoma , biochemistry
Summary The prognosis of angiosarcoma remains very poor, even with combined, multimodal therapy. We report a case with partial response of angiosarcoma of the scalp to sorafenib, which is a new oral, molecular, targeted, multiple‐kinase inhibitor. In addition, we confirmed, using immunohistochemistry, that sorafenib suppressed the expression of vascular endothelial growth factors and their receptors on the angiosarcoma tumour cells, and decreased cell numbers by inhibiting cellular proliferation.